News about Clinical Trials

Novo Nordisk Higher-Dose Wegovy Shows 28 Percent Weight Loss in Early Responders

Novo Nordisk reports new analyses showing higher-dose Wegovy helped early responders achieve up to 28 percent weight loss, highlighting its effectiveness for obesity treatment regardless of response speed.

Clinical Trials | 13/05/2026 | By News Bureau |  213

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Clinical Trials | 13/05/2026 | By News Bureau |  198

Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954

Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.

Clinical Trials | 12/05/2026 | By News Bureau |  395

Hengrui Pharma and Braveheart Bio Report Positive Phase 2 Results for Cardiac Therapy HRS/BHB-1893 in nHCM

Hengrui Pharma and Braveheart Bio have reported positive Phase 2 clinical trial results for investigational cardiac therapy HRS/BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, demonstrating improvements in cardiac function, biomarkers and patient outcomes.

Clinical Trials | 12/05/2026 | By News Bureau |  358

Mabwell Secures FDA Clearance for 9MW5211 Clinical Trial Application

Mabwell receives US Food and Drug Administration (FDA) IND clearance for 9MW5211, a novel antibody therapy being developed for Inflammatory Bowel Disease (IBD) clinical studies.

Clinical Trials | 11/05/2026 | By News Bureau |  205

Bayer Reports Positive Phase 3 Results for Investigational Cardiac Amyloidosis Imaging Agent

REVEAL study demonstrates strong diagnostic sensitivity and specificity of I 124 evuzamitide PET/CT radiotracer for detecting cardiac amyloidosis, supporting plans for regulatory discussions with the FDA.

Clinical Trials | 08/05/2026 | By News Bureau |  213

Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27

The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.

Clinical Trials | 08/05/2026 | By News Bureau |  282

Alebund Pharmaceuticals Completes Enrollment in Global Phase 3 Trial for AP301 Hyperphosphatemia Therapy

Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.

Clinical Trials | 07/05/2026 | By News Bureau |  190

JNJ-4804 Co-Antibody Shows Promise in Refractory Inflammatory Bowel Disease

Johnson & Johnson (J&J) investigational JNJ-4804 co-antibody shows superior clinical and endoscopic outcomes in refractory Inflammatory Bowel Disease (IBD), supporting phase 3 advancement with dual IL-23 and TNF pathway targeting.

Clinical Trials | 07/05/2026 | By News Bureau |  226

Anteris Technologies Global Corp. Begins US Enrollment in PARADIGM Trial for DurAVR Heart Valve

Anteris marks first patients successfully treated in US as global trial evaluates safety and effectiveness of DurAVR THV against existing transcatheter aortic valve therapies.

Clinical Trials | 06/05/2026 | By News Bureau |  175